Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06466746
Other study ID # UREC 24/02
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date September 2025

Study information

Verified date June 2024
Source University of Reading
Contact Julie A Lovegrove, BSc PhD
Phone 0118 378
Email j.a.lovegrove@reading.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High levels of animal proteins (meat) in the diet are linked with a greater risk of developing heart disease and other long-term health conditions. Recently there has been a shift to plant-based diets including plant proteins such as pulses, defined as beans, peas, chickpeas and lentils. Pulses are a nutritious and sustainable form of plant protein which are rich in fibre and iron. Despite this, the UK population does not consume the recommended daily amount of pulses (80g/day equivalent to a large handful). In contrast, bread is commonly consumed but very little is known about how bread enriched with pulses influences the amount of iron that is digested and absorbed by the body as well as risk factors for developing heart disease and type 2 diabetes. The main purpose of this randomised controlled cross-over study is to determine how consuming bread enriched with pulses (in the form of faba bean flour at approximately 40% enrichment) compared with conventional white bread (100% wheat flour) influences the amount of iron absorbed in healthy males and females aged 18-50 years with low iron stores. Secondary aims are determining the effects on blood fats and sugar (glucose) and on feelings of fullness (also known as satiety) after eating the bread enriched in pulses and conventional white bread. Participants will be required: - To attend for seven study visits over a period of 60 days. - Consume a breakfast meal containing either the faba bean-enriched bread or conventional bread over two study periods, each consisting of one 7 hour study visit and two consecutive visits of 2 hours in duration. After 28 days, participants will return for the second study period as above, with a final study visit conducted 28 days later. - Give blood samples during 2 x 7 hour study visits - Complete visual analogue scales to rate appetite after consuming the faba bean-enriched and conventional white bread. - Record dietary intake prior to and during the study period.


Description:

Since higher dietary intakes of animal protein (meat) are linked with heart disease and other long-term health problems, there has been a shift in recent years to consuming more plant-based foods. Legumes (e.g. beans) provide a sustainable and nutritious source of protein and are higher in fibre and micronutrients (such as iron) compared with staple cereals. Higher intakes of pulses lower blood sugar and fat levels, increase feelings of fullness (satiety) and reduce blood pressure. The higher iron content in mature faba beans may also help to reduce iron-deficiency anaemia, the most common diet-related deficiency. However, studies have suggested that the absorption of iron from pulses (known as bioavailability) is lower than from meat due to the presence of compounds in plants that interfere with absorption (anti-nutrients). Processing techniques such as milling of faba beans are considered to lower or even eliminate these compounds. In the Raising the Pulse (RtP) project, flour milled from homegrown faba beans will be used to produce a pulse-enriched loaf which could be adopted in the UK diet and benefit both health and the environment. However, very little is known about how bread enriched with pulses may influence firstly, iron bioavailability and secondly, blood sugar and fat levels which are common risk factors for developing heart disease and diabetes. This randomised controlled cross-over study will aim to recruit 16 healthy, non-anaemic males and females with low iron stores. Aside from the screening visit where participants will be assessed for eligibility and consent for participation gained, this study will involve seven study visits. The first study visit (Day 1) will be approximately 7 hours (420 minutes) in duration and participants will be randomly assigned to consume either the faba bean-enriched bread or the conventional white bread along with a drink containing iron-57, a naturally occurring non-radioactive form of iron found in very low levels in the diet (stable isotope) to measure iron absorption. Blood samples will be collected to measure blood haemoglobin, sugar and fat levels as well as hormones known to impact appetite, and participants will be asked to complete visual analogue scales to rate their appetite. At the visit, an ad-libitum (unrestricted) meal will be provided 6 hours after eating the test breakfast and the amount of food eaten will be used to assess satiety. Participants will then return on days 2 and 3 to consume the same test meal and complete visual analogue scales to rate appetite for 2 hours. At day 30, participants will return for the second 7 hour (420 minute) study visit to consume the other type of bread and return on days 31 and 32 for the shorter study visits. The day 30 fasting blood sample will be used to measure the enrichment of blood haemoglobin with iron-57 to determine the amount of iron absorbed from the test bread given on day 0. On day 60, participants will return to the clinical unit to give a final fasting blood sample to measure iron bioavailability (enrichment of blood haemoglobin with iron-57) from the test bread given on day 30. Dietary intake will also be recorded.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 16
Est. completion date September 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Non-anaemic, males and pre-menopausal females (must have regular periods) - Aged 18-50 years old - BMI between 19 - 30 kg/m2 - Low iron stores (serum ferritin between 13-40 µg/L for females and 30-90 µg/L for males) Exclusion Criteria: - Food allergies or intolerances to faba beans (favism) or gluten - Diagnosed with anaemia (haemoglobin <115 g/L for females or <130 g/L for males) or haemochromatosis - C-reactive protein (>3mg/L) - Smokers - A history of alcohol abuse (> 14 units/ week) - CVD or medical history of MI or stroke in the past 12 months - Diabetes (fasting glucose >7.0 mmol/L) - Kidney, liver, pancreas or intestinal disease, gastrointestinal disorder or use of drugs likely to alter gastrointestinal function - Pregnancy, planning a pregnancy in the next six months or breastfeeding - Peri- and post-menopausal women or women with irregular periods - Planning on a weight-reducing regimen (lost >3kg in last 6 months) - Parallel participation in another intervention study - Hypertension (blood pressure > 140/90 mmHg), cancer, taking medication for hyperlipidaemia (statins), or inflammation - Taking vitamin or mineral supplements - Donated blood in the last 3 months - Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (such as a pacemaker)

Study Design


Intervention

Other:
Raising the Pulse faba bean-enriched bread
100 g of white bread produced using 40% faba bean enriched flour and 60% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
Conventional White Bread
100 g of white bread produced using 100% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.

Locations

Country Name City State
United Kingdom Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading Reading Berkshire

Sponsors (3)

Lead Sponsor Collaborator
University of Reading King's College London, University of Leeds

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Lovegrove JA, O'Sullivan DM, Tosi P, Millan E, Todman LC, Bishop J, Chatzifragkou A, Clegg ME, Hammond J, Jackson KG, Jones PJ, Lignou S, Macready AL, McMeel Y, Parker J, Rodriguez-Garcia J, Sharp P, Shaw LJ, Smith LG, Tebbit M. 'Raising the Pulse': The environmental, nutritional and health benefits of pulse-enhanced foods. Nutr Bull. 2023 Mar;48(1):134-143. doi: 10.1111/nbu.12601. Epub 2023 Jan 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in the enrichment of whole blood haemoglobin with iron-57 stable isotope 30 days after consuming the faba bean-enriched bread and conventional bread. The measurement of iron-57 in whole blood is a validated method for determining the absorption of iron from the bread given in the test meals (also known as bioavailability) Day 0 (baseline), day 30 and day 60
Secondary Fasting concentrations of iron status markers Serum ferritin (a measure of the level of iron stored by the body) and soluble transferrin receptor (a measure of functional iron status) will be measured by immunoassay. Day 0 (baseline), day 30 and day 60
Secondary Fasting concentration of C-reactive protein (a marker of inflammation) Inflammation, which is characterised by the acute-phase response to infection, can directly affect the concentrations of most iron status markers. C-reactive protein will be measured in the fasting blood sample collected at each study visit to aid the interpretation of the data for the iron status markers. Day 0 (baseline), day 30 and day 60
Secondary Fasting levels of the full blood count parameters The level of white blood cells, red blood cells, platelets, haematocrit and haemoglobin in the whole blood sample will be measured using a haematology analyser. Day 0 (baseline), day 30 and day 60
Secondary Fasting concentration of total cholesterol, high-density lipoprotein-cholesterol, triacylglycerol and non-esterified fatty acids. Serum lipids will be measured directly using a clinical chemistry analyser. Day 0 (baseline), day 30 and day 60
Secondary Fasting low-density lipoprotein-cholesterol concentration The low-density lipoprotein-cholesterol concentration will be calculated from the total cholesterol, high-density lipoprotein-cholesterol and triacylglycerol concentrations using the Friedewald formula. Day 0 (baseline), day 30 and day 60
Secondary Postprandial concentrations of lipids after consuming the faba bean-enriched bread and control bread. Serum triacylglycerol and non-esterified fatty acids will be measured in the postprandial blood samples collected for 360 minutes after each acute test meal. Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion.
Secondary Fasting glucose concentration Serum glucose will be measured using a clinical chemistry analyser. Day 0 (baseline), day 30 and day 60
Secondary Fasting insulin concentration Serum insulin will be measured using an enzyme-lined immunosorbent assay. Day 0 (baseline), day 30 and day 60
Secondary Fasting estimate of insulin resistance HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the glucose and insulin data. Day 0 (baseline), day 30 and day 60
Secondary Fasting estimate of insulin sensitivity QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the glucose and insulin data. Day 0 (baseline), day 30 and day 60
Secondary Postprandial glucose concentrations after consuming the faba bean-enriched bread and control bread. Serum glucose will be measured in the postprandial blood samples collected for 360 minutes after each acute test meal. Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion
Secondary Postprandial insulin concentrations after consuming the faba bean-enriched bread and control bread. Serum insulin will be measured in the postprandial blood samples collected for 360 minutes after each acute test meal. Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion
Secondary Fasting and postprandial concentrations of gut hormones C-peptide, PYY, GIP and GLP-1 will be measured using a Luminex multiplex assay. Acute study on Days 0 and 30, blood taken before meal ingestion at 0 minutes and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion
Secondary Fasting apolipoprotein B concentration Serum apolipoprotein B will be measured using a clinical chemistry analyser. Day 0 (baseline), day 30 and day 60
Secondary Postprandial apolipoprotein B concentrations after consuming the faba bean-enriched bread and control bread. Serum apolipoprotein B concentrations will be measured using a clinical chemistry analyser. Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 60, 120, 180, 240, 300 and 360 minutes post meal ingestion.
Secondary Fasting and postprandial concentrations of amino acids Individual amino acids Acute study on Days 0 and 30, blood taken before eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion
Secondary Height Height will be measured to the nearest cm using a stadiometer Day 0 (baseline)
Secondary Body weight Body weight will be measured using a Tanita scale. Day 0 (baseline), day 30 and day 60
Secondary Body fat percentage Body fat percentage will be measured using a Tanita scale by bioelectrical impedance. Day 0 (baseline), day 30 and day 60
Secondary Body fat mass and lean mass Body fat mass and lean mass will be measured using a Tanita scale by bioelectrical impedance. Day 0 (baseline), day 30 and day 60
Secondary Body mass index calculation Body mass index will be calculated using the body weight (kg) and height data (m). Day 0 (baseline), day 30 and day 60
Secondary Waist and hip circumferences A non-stretch tape measure will be used to measure the waist and hip circumferences in cm. Day 0 (baseline), day 30 and day 60
Secondary Clinic blood pressure Systolic blood pressure, diastolic blood pressure and pulse pressure Day 0 (baseline), day 30 and day 60
Secondary Postprandial feelings of satiety_7 hour study visit (long day) 100 mm visual analogue scale. This scale is well validated for measuring appetite and satiety. Each rating score is out of 100. Acute study on Days 0 and 30, prior to eating the test meal (0 minutes) and then at 15, 30, 60, 120, 240 and 360 minutes post meal ingestion
Secondary Postprandial feelings of satiety_2 hour study visit (short day) 100 mm visual analogue scale. This scale is well validated for measuring appetite and satiety. Each rating score is out of 100. Days 1, 2, 31 and 32 prior to eating the test meal (0 minutes) and then at 15, 30, 60 and 120 minutes post meal ingestion.
Secondary Habitual dietary intake of the study participants Record of food and drink intake prior to each study visit. Day 0 (baseline), day 30 and day 60
Secondary Fasting blood samples stored for future ethically approved research related to the project aims and objectives. Spare whole blood and plasma/serum samples will be collected and biobanked for future research Day 0 (baseline), day 30 and day 60
Secondary Postprandial blood samples stored for future ethically approved research related to the study aims and objectives. Spare plasma/serum samples will be biobanked for future research Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion.
See also
  Status Clinical Trial Phase
Completed NCT04435574 - Lactoferrin for Treatment of Iron Deficiency Anemia. Phase 4
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Not yet recruiting NCT05050851 - Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04626414 - Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers Phase 1
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Recruiting NCT05304442 - IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department Phase 3
Enrolling by invitation NCT03897673 - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas N/A
Completed NCT05047211 - Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia Phase 4
Not yet recruiting NCT06061393 - Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia Phase 4
Completed NCT05190263 - Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
Completed NCT03318055 - Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients
Completed NCT04631679 - Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)
Recruiting NCT05225545 - Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis Phase 3
Recruiting NCT03347513 - Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy? Phase 4
Recruiting NCT04708665 - Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India
Completed NCT02404012 - Iron Supplement to Improve Iron Status Following Bariatric Surgery N/A
Completed NCT04137354 - Iron and Vitamin A in School Children N/A
Not yet recruiting NCT06096103 - A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin c and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemia N/A
Completed NCT03156712 - Iron Absorption From Iron-enriched Aspergillus Oryzae N/A